Medtronic (NYSE:MDT) Price Target Raised to $100.00

Medtronic (NYSE:MDT) had its price objective upped by equities research analysts at BTIG Research from $91.00 to $100.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. BTIG Research’s price target would indicate a potential upside of 7.82% from the company’s current price.

Other equities analysts have also issued reports about the company. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Deutsche Bank Aktiengesellschaft cut their price objective on Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Leerink Partners reduced their price objective on Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Sanford C. Bernstein decreased their target price on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.17.

Medtronic Stock Up 2.3%

Medtronic stock traded up $2.10 during midday trading on Tuesday, hitting $92.75. 10,570,797 shares of the stock were exchanged, compared to its average volume of 8,856,479. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The business’s 50-day moving average price is $85.81 and its 200-day moving average price is $85.48. The stock has a market capitalization of $118.71 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. During the same quarter last year, the business posted $1.26 EPS. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts expect that Medtronic will post 5.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Institutional Trading of Medtronic

Hedge funds have recently made changes to their positions in the company. Anfield Capital Management LLC grew its stake in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Monetary Solutions Ltd bought a new stake in Medtronic in the 4th quarter valued at about $27,000. Acumen Wealth Advisors LLC purchased a new stake in Medtronic during the fourth quarter valued at about $29,000. IAG Wealth Partners LLC purchased a new stake in Medtronic during the second quarter valued at about $30,000. Finally, Imprint Wealth LLC bought a new position in Medtronic during the third quarter worth about $31,000. 82.06% of the stock is currently owned by institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported adjusted earnings of $1.45 per share, above the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, exceeding expectations of approximately $9.55 billion. Growth was broad-based across cardiovascular, neuroscience, medical surgical and diabetes businesses. Medtronic Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Cardiovascular revenue climbed 19.5% on reported growth, supported by demand for devices used in complex procedures. Neuroscience, medical surgical and diabetes revenue also grew at double-digit rates, reinforcing the company’s growth outlook. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Management raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75% and set adjusted EPS guidance at $5.94-$6.00, citing improved margins, portfolio strength and newer growth platforms. Medtronic reports first quarter fiscal 2027 results
• Positive Sentiment: Medtronic committed approximately $700 million to a partnership with Cornerstone Robotics, gaining distribution rights for the Sentire surgical system in select markets outside the U.S. The company also agreed to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic valve replacement procedures. These moves broaden its robotics and structural-heart offerings. Medtronic Announces Strategic Partnership with Cornerstone Robotics
• Positive Sentiment: Unusually heavy call-option activity and generally favorable analyst opinions, along with Medtronic’s dividend yield above 3%, added to the constructive investor sentiment.
• Neutral Sentiment: The stock showed relative strength even as broader U.S. markets traded lower, suggesting the earnings beat and raised outlook were outweighing broader risk-off conditions.
• Negative Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus estimate, and the sizeable robotics investment could increase near-term execution and integration risks.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).